Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.46 |
| ▸ | CD38 | P28907 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3642682 | 0.92 | L3MBTL1 (0.50) | MAPTL3MBTL1CRHR1NR4A2CD38 | |
| SCHEMBL3054520 | 0.86 | CD38 (0.60) | MAPTL3MBTL1CRHR1NR4A2CD38 | |
| SCHEMBL3061296 | 0.84 | MAPT (0.50) | MAPTL3MBTL1CRHR1NR4A2CD38 | |
| SCHEMBL3051573 | 0.80 | NR4A2 (0.48) | MAPTL3MBTL1CRHR1NR4A2CD38 | |
| SCHEMBL3063558 | 0.78 | NR4A2 (0.71) | MAPTL3MBTL1CRHR1NR4A2CD38 | |
| SCHEMBL318514 | 0.76 | MAPT (0.64) | MAPTL3MBTL1CRHR1NR4A2KDM4E | |
| SCHEMBL7690466 | 0.74 | MAPT (0.67) | MAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL661993 | 0.73 | MAPT (0.60) | MAPTL3MBTL1CRHR1NR4A2KDM4E | |
| SCHEMBL317207 | 0.73 | MAPT (0.60) | MAPTL3MBTL1CRHR1NR4A2KDM4E | |
| SCHEMBL9413346 | 0.73 | SMN1; SMN2 (0.56) | MAPTKDM4ELMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420670-B2 | 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-2178842-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024611-A2 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222346-A1 | 4-BENZYLAMINOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GDI2, GDI1, NQO2 | MAPT 2051/4885L3MBTL1 4811/4885CRHR1 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.